Mayne Pharma Group Ltd
ASX:MYX
P/S
Price to Sales
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
Market Cap | P/S | ||||
---|---|---|---|---|---|
AU |
Mayne Pharma Group Ltd
ASX:MYX
|
569.5m AUD | 2 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | |
US |
Eli Lilly and Co
NYSE:LLY
|
722.3B USD | 20.1 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 16.5 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
360.8B USD | 4.2 | ||
US |
Merck & Co Inc
NYSE:MRK
|
329.4B USD | 5.4 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
191.1B GBP | 5 | ||
CH |
Novartis AG
SIX:NOVN
|
181.1B CHF | 3.4 | ||
CH |
Roche Holding AG
SIX:ROG
|
180B CHF | 3.1 | ||
US |
Pfizer Inc
NYSE:PFE
|
158.1B USD | 2.9 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.